期刊
CANCER RESEARCH
卷 76, 期 2, 页码 239-250出版社
AMER ASSOC CANCER RESEARCH
DOI: 10.1158/0008-5472.CAN-15-0748
关键词
-
类别
资金
- Minnesota Ovarian Cancer Alliance
- Fred C. and Katherine B. Andersen Foundation
- Marsha Rivkin Center for Ovarian Cancer Research
- Mayo Clinic Ovarian Cancer SPORE [P50-CA136393]
- Mayo Clinic Cancer Center Support Grant [P30-CA015083-25]
The PD-1:PD-L1 immune signaling axis mediates suppression of T-cell-dependent tumor immunity. PD-1 expression was recently found to be upregulated on tumor-infiltrating murine (CD11c(+)CD11b(+)CD8(-)CD209a(+)) and human (CD1c(+)CD19(-)) myeloid dendritic cells (TIDC), an innate immune cell type also implicated in immune escape. However, there is little knowledge concerning how PD-1 regulates innate immune cells. In this study, we examined the role of PD-1 in TIDCs derived from mice bearing ovarian tumors. Similar to lymphocytes, TIDC expression of PD-1 was associated with expression of the adapter protein SHP-2, which signals to NF-kappa B; however, in contrast to its role in lymphocytes, we found that expression of PD-1 in TIDC tonically paralyzed NF-kappa B activation. Further mechanistic investigations showed that PD-1 blocked NF-kappa B-dependent cytokine release in a SHP-2-dependent manner. Conversely, inhibition of NF-kappa B-mediated antigen presentation by PD-1 occurred independently of SHP-2. Collectively, our findings revealed that PD-1 acts in a distinct manner in innate immune cells compared with adaptive immune cells, prompting further investigations of the signaling pathways controlled by this central mediator of immune escape in cancer. (C) 2015 AACR.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据